As filed with the Securities and Exchange Commission on August 6, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
NOVAVAX, INC.
(Exact name of Registrant as specified in its charter)
| Delaware |
21 Firstfield Road, Gaithersburg, Maryland 20878 |
22-2816046 |
| (State of incorporation) | (Address of principal executive offices) | (I.R.S. Employer Identification No.) |
Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan
Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan
(Full Title of the Plan)
Mark J. Casey
Executive Vice President, Chief Legal Officer & Corporate Secretary
Novavax, Inc.
21 Firstfield Road
Gaithersburg, Maryland 20878
(240) 268-2000
(Name, Address and Telephone Number, Including Area Code, of Agent For Service)
with copies to:
Wesley C. Holmes
Elisabeth M. Martin
Latham & Watkins LLP
200 Clarendon Street
Boston, Massachusetts 02116
(617) 880-4500
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | x | Accelerated filer | ¨ |
| Non-accelerated filer | ¨ | Smaller reporting company | ¨ |
| Emerging growth company | ¨ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering (i) 1,310,300 additional shares of common stock, par value $0.01 per share (the “Common Stock”), of Novavax, Inc. (the “Registrant”) that may be issued and sold pursuant to the Registrant’s Amended and Restated 2013 Employee Stock Purchase Plan, as amended (the “2013 Plan”), and (ii) 9,400,000 additional shares of Common Stock that may be issued pursuant to awards under the Registrant’s Amended and Restated 2015 Stock Incentive Plan (the “2015 Plan”), for which prior Registration Statements on Form S-8 (File Nos. 333-190599, 333-206354, 333-213069,333-219829, 333-226498, 333-233133, 333-243758, 333-258517, 333-266681, 333-273791 and 333-281376) are effective.
Pursuant to General Instruction E of Form S-8, the contents of the above referenced prior Registration Statements on Form S-8, including any amendments thereto, filed with the Securities and Exchange Commission, relating to the 2013 Plan and the 2015 Plan are incorporated herein by reference.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
INDEX OF EXHIBITS
| * | Filed herewith |
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Gaithersburg, state of Maryland on August 6, 2026.
| NOVAVAX, INC. | ||
| By: | /s/ John C. Jacobs | |
| John C. Jacobs | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints John C. Jacobs, James P. Kelly and Mark J. Casey, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Novavax, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||
| /s/ John C. Jacobs | President and Chief Executive Officer | August 6, 2026 | ||
| John C. Jacobs | and Director (Principal Executive Officer) | |||
| /s/ James P. Kelly | Executive Vice President, Chief Financial Officer | August 6, 2026 | ||
| James P. Kelly | and Treasurer (Principal Financial and Accounting Officer) | |||
| /s/ David M. Mott | Chairman of the Board of Directors | August 6, 2026 | ||
| David M. Mott | ||||
| /s/ Gregg H. Alton | Director | August 6, 2026 | ||
| Gregg H. Alton | ||||
| /s/ Richard H. Douglas | Director | August 6, 2026 | ||
| Richard H. Douglas | ||||
| /s/ Rachel K. King | Director | August 6, 2026 | ||
| Rachel K. King | ||||
| /s/ Margaret G. McGlynn | Director | August 6, 2026 | ||
| Margaret G. McGlynn | ||||
| /s/ Charles W. Newton | Director | August 6, 2026 | ||
| Charles W. Newton | ||||
| /s/ Richard J. Rodgers | Director | August 6, 2026 | ||
| Richard J. Rodgers | ||||
| /s/ John W. Shiver, Ph.D. | Director | August 6, 2026 | ||
| John W. Shiver, Ph.D. |